Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MMV Obtains $115m Grant From Gates Foundation
Medicines for Malaria Venture (MMV) has received its fifth grant from the Bill & Melinda Gates Foundation, to fund its research and development pipeline with an additional $115m
Medicines for Malaria Venture (MMV) has received its fifth grant from the Bill & Melinda Gates Foundation, to fund its research and development pipeline with an additional $115m
ChemDiv of San Diego has said that its wholly owned subsidiary Chemical Diversity Research Institute (CDRI ) of Moscow, Russia, has been chosen by Viriom of Moscow, as
ChemPartner, a Shanghai based pre-clinical research company, is planning to enter into the European market by establishing ChemPartner Europe in Copenhagen in November – reported Copenhagen Capacity, the
XenoPort has initiated a phase 2b clinical trial of arbaclofen placarbil (AP), also known as XP19986, in patients with gastroesophageal reflux disease (GERD), who remain symptomatic despite treatment
QLT has restructured its agreement with Novartis to simplify the relationship, under which, effective January 1, 2010, it will, among other things, receive exclusive US rights to the
Human Genome Sciences, (HGSI) has achieved a $75m milestone payment from Novartis, related to successful completion of the phase 3 development program and the decision to submit applications
Alnara Pharmaceuticals (Alnara) has reported results from an international, phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase. Reportedly, liprotamase is a novel
Talecris Biotherapeutics (Talecris) has received approval from the FDA for Prolastin-C (Alpha1-Proteinase Inhibitor [Human]), a more concentrated version of Prolastin produced using advances in manufacturing technology. Like Prolastin,
Quotient Biodiagnostics (Quotient) has received FDA approval for its biologics license application (BLA) for the first 15 monoclonal antibodies in its proprietary line of transfusion diagnostics. These products
Tracon Pharmaceuticals (Tracon) has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Under the terms of the agreement, both the companies